Results: Both GnRH-I and GnRH-II increased the intracellular Ca
source or via mobilization of Ca 2ϩ from internal Ca 2ϩ stores. Interestingly, the [Ca 2ϩ ] i increase was mediated by activation of the ryanodine receptor but not the inositol trisphosphate receptor. Trptorelix-1, a novel GnRH-II antagonist but not cetrorelix, a classical GnRH-I antagonist, completely inhibited the GnRH-II-induced [Ca 2ϩ ] i increase. Concurrently at high concentrations, trptorelix-1 and cetrorelix inhibited GnRH-I-induced [Ca 2ϩ ] i increase, whereas at low concentrations they exerted an agonistic action, inducing Ca 2ϩ influx. High concentrations of trptorelix-1 but not cetrorelix-induced prostate cancer cell death, probably through an apoptotic process. Using photoaffinity labeling with 125 I-[azidobenzoyl-D-Lys 6 ]GnRH-II, we observed that an 80-kDa protein specifically bound to GnRH-II.
Conclusions:
This study suggests the existence of a novel GnRH-II binding protein, in addition to a conventional GnRH-I receptor, in prostate cancer cells. These data may facilitate the development of innovatory therapeutic drugs for the treatment of prostate cancer. P ROSTATE CANCER IS the most common malignancy in men and the second leading cause of cancer-related deaths in Western countries (1) . Initial treatment of prostate cancer is hormonal therapy to remove or decrease serum androgen, a potential growth stimulant for prostate cancer. However, after an initial regression, most prostate cancers become resistant to this loss of androgens and progress further with eventual death (2) . Thus, development of effective therapeutic drugs for androgen-independent prostate cancer is of utmost concern to oncologists.
Hormonal therapies to treat benign prostatic hyperplasia or androgen-dependent prostate cancers include drugs that target the GnRH receptor (3) (4) (5) . The GnRH isoform synthesized in the hypothalamus is termed GnRH-I as opposed to a second form of GnRH (GnRH-II) that is widely expressed in the brain as well as in peripheral reproductive and immune tissues (6 -12) . GnRH-I stimulates the secretion of pituitary gonadotropins, LH, and FSH, which in turn modulates the synthesis and secretion of androgens from the testis. Chronic administration of a GnRH-I superagonist was found to down-regulate the GnRH receptor, resulting in a marked reduction in circulating levels of androgens (3) . Alternatively, inactivation of the GnRH receptor by a GnRH-I antagonist is also effective in reducing androgen levels (4, 5) .
Recently a series of studies demonstrated the direct action of GnRH-I on prostate cancer cells. A GnRH-I superagonist exerted a direct inhibitory action on epidermal growth factor-or IGF-induced prostate cancer cell proliferation (13, 14) . The authors suggested that this effect may be meditated by the pituitary type GnRH receptor (the mammalian type 1 GnRH receptor distinct from the type 2 GnRH receptor found in the monkey) because they observed expression of the mammalian type 1 GnRH receptors by RT-PCR and Western blot analysis (15) . The mammalian type 1 GnRH receptor in the pituitary and other cells is known to be coupled to G q/11 , which in turn activates phospholipase C (PLC), producing inositol trisphosphate (IP 3 ) and diacylglycerol (16) . However, it has been suggested that, in prostate cancer cells, GnRH activates a G i -linked signaling cascade (15) . The exact reason for such a discrepancy of the signaling pathways from the same receptor is unclear. Alternatively, it may be ascribed to the presence of uncharacterized GnRH receptors in prostate cancer cells that may trigger a different signaling cascade.
Another question raised from these studies is whether GnRH-II could be involved in the regulation of prostate cancer cell growth because it is likely to have diverse functions in reproductive and immune tissues (6 -12) . It is noteworthy that, in human endometrial and ovarian cancer cells, GnRH-II appears to be a more potent inhibitor of cell proliferation than GnRH-I (17). GnRH-II exhibits a differential hormonal regulation pattern in human granulosa-luteal cells (11) . Recently it was found that GnRH-II, produced by human T cells, triggers laminin receptor gene expression and cell migration (12) . Interestingly, GnRH-II-induced laminin receptor gene expression is not blocked by the GnRH-I antagonist cetrorelix (12) , suggesting the existence of an uncharacterized receptor for GnRH-II in human. However, involvement of GnRH-II and its novel receptor in the regulation of prostate cancer cell growth has not been carefully studied.
Recently we and others identified the receptors having a higher sensitivity/affinity for GnRH-II than GnRH-I in nonmammalian species, referred to as nonmammalian GnRH receptors (18, 19) . Furthermore, the functional receptor for GnRH-II was cloned from the monkey and called mammalian type 2 GnRH receptor (20 -22) . In humans, the genes for the mammalian type 2 GnRH receptor are localized in chromosomes 1 and 14 and are expressed in a variety of tissues including brain (23) . However, these genes are thought to be nonfunctional pseudogenes due to the introduction of a premature stop codon (23, 24) . Although alternative splicing patterns to circumvent the frame-shift that allows the production of a two-membrane domain protein has been suggested, the functionality of such a protein is still in question (25) .
Although genetics-based studies suggest the absence of a functional type 2 GnRH receptor in humans, many physiological and pharmacological findings raise the possibility of novel human receptors for GnRH-II (11, 12, 17) . Based on the characterization of GnRH-II receptors in both nonmammalian and mammalian species (26 -28), we designed specific GnRH-II analogs (22, 29, 30) . In the present study, using these GnRH-II analogs, we provide evidence for the possible involvement of a novel GnRH-II-binding protein in cell signaling and death of androgen-independent prostate cancer cells. We also demonstrate that a novel GnRH-II antagonist, trptorelix-1, induces prostate cancer cell death probably via an apoptotic process.
Materials and Methods

GnRH and its analog
GnRH-I (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 ) and [des-Gly 10 , d-Trp 6 ]-GnRH-I (GnRH-Ia) were purchased from Sigma (St. Louis, MO). ]-GnRH-II were synthesized by AnyGen (Gwangju, Korea).
Cell culture
DU-145 and LNCaP cells were obtained from Korea Cell Bank (Seoul, Korea) and American Type Culture Collection (Manassas, VA), respectively. PPC-1 (31), ALVA-41 (32) , and TSU-Pr1 (33) cells were obtained from Dr. J. Y. Bahk (Gyeongsang National University, Chinju, Korea) with the permissions of their original developers. DU-145, ALVA-41, TSU-Pr1, PPC-1, MCF-7, CV-1, HEK-293, and GH 3 cells were cultured at 37 C in DMEM containing 10% heat-inactivated fetal bovine serum (FBS), 1 mm glutamate, 100 U penicillin, and 100 g/ml streptomycin. LNCaP cells were grown in RPMI 1640 medium containing 10% FBS at 37 C.
Establishment of stable cell lines using retroviral expression vectors
The establishment of stable cell lines expressing bullfrog GnRHR (bfGnRHR)-3 or rat GnRHR has been previously described (22, 34) . Briefly, the entire open reading frames of bfGnRHR-3 and rat GnRH receptor (GnRHR) were cloned into the retrovirus expression vector, pLXSN (Clontech, Palo Alto, CA) at the EcoRI and XhoI sites. The pLXSN retroviral vectors containing either bfGnRHR-3 or rat GnRHR were transfected in the dual-tropic packaging cell line PT67 using the Superfect transfection kit (QIAGEN, Chatsworth, CA). The cells were treated with 25 mm chloroquinine (Sigma) 1 h before transfection, and the media were replenished (DMEM, 10% FBS). After 24 h, the cells were treated with 800 g/l G418 (Clontech) for 2 wk. Large healthy colonies were selected and expanded. The presence of the stably expressed genes was confirmed by RT-PCR and inositol phosphate (IP) assay. The culture media soup was used for infection of GH 3 cells with retroviruses containing the GnRH receptors. Two days after infection, GH 3 cells were selected with G418 for 2 wk, and selected clones were expanded. GH 3 cell lines expressing rat GnRHR or bfGnRHR-3 with the highest IP fold induction were chosen and maintained in DMEM containing 10% FBS until use.
Generation of recombinant adenovirus
Ad-bf2-SDY, an E1-deleted adenovirus expressing bfGnRHR-2-SDY mutant, was generated by Neurogenex (Seoul, Korea). Briefly, DNA encoding bfGnRHR-2-SDY (30) was inserted into the pShuttle-cytomegalovirus vector (Clontech). The pShuttle-cytomegalovirus with bfGnRHR-2-SDY was linearized with PmeI and cotransformed into BJ 5183 Escherichia coli along with the pAdEasy-1 (Clontech) adenoviral vector. Transformed cells were overlaid on kanamycin-containing agarose plates, and individual colonies were checked for the presence of the proper recombinant. After sequence confirmation, recombinant adenoviral stocks were expanded by infection of HEK-293A cells, followed by extraction and CsCl gradient purification. Viral titers were determined using plaque assays and reported as multiplicity of infection (MOI), in which one MOI represents one plaque-forming unit/plate. Viruses expressing enhanced green fluorescent protein (Ad-EGFP) were used as controls.
Cell binding assay
GnRH-II and GnRH-Ia were iodinated with the chloramine-T (Sigma) method and purified by chromatography on a Sephadex G-25 (Sigma) column in 0.01% acetic acid and 0.1% BSA. Cells (3 ϫ 10 5 cells/well) were grown in 12-well plates for 24 h before assay. The cells were washed with warm PBS and incubated at 4 C for 60 min with the iodinated ligand (60,000 -80,000 cpm/well) in DMEM containing 0.1% BSA in the absence or presence of cold GnRH (10 m). The cells were then washed twice with PBS. After solubilizing the cells in 1% sodium dodecyl sulfate (SDS) and 0.2 m NaOH, radioactivity was determined.
RT-PCR analysis
Total RNA was isolated from ALVA-41, DU-145, PPC-1, TSU-Pr1, HEK-293, and HeLa cells using Tri-reagent (Sigma). Five micrograms of total RNA were reverse transcribed with Superscript II Ribonuclease H Ϫ reverse transcriptase (Life Technologies, Inc., Rockville, MD), according to a provided protocol. The first-strand cDNA was amplified by PCR using the following primers: hGnRHR1-F (5Ј-CTTGAAGCTCTGTCCTGGG-3Ј; located at Ϫ6 to Ϫ25 from the translation start point); hGnRHR1-R (5Ј-AAGCTAGGGGCCTCGTGATA-3Ј; 426 -445); hGnRHR2e1-F (5Ј-ATGTCTGCAGGCAACGG-3Ј; 380 -396); hGnRHR2e1-R (5Ј-CTGGGG-CAAGGCAAGCAGGAAACT-3Ј; 865-888); hGnRHR2e2-F (5Ј-CTGTT-CCTGTTCCACACGG-3Ј; 880 -907); hGnRHR2e2-R (5Ј-CATGGCTCC-CCTTCCTT-3Ј; 1083-1099); F-␤-actin (5Ј-CTGAAGTCACCCATTGAA-CATGGC-3Ј); and R-␤-actin (5Ј-CAGAGCAGTAATCTCCTTCTGCAT-3Ј). The PCR cycling parameters were: denaturation at 94 C for 5 min followed by 40 cycles of denaturation at 94 C for 30 sec, annealing at 56 C for 30 sec, and extension at 72 C for 45 sec. The PCR products were separated on a 1.5% agarose gel, stained with ethidium bromide, and photographed under a UV light source. Reactions were terminated by aspirating the medium and adding 1 ml 10 mm formic acid. After 30 min, the formic acid extracts were transferred to a column containing Dowex anion-exchange resin (Bio-Rad Laboratories, Hercules, CA). Total IP was eluted with 1 m ammonium formate and 0.1 m formic acid, and radioactivity was determined using a liquid scintillation counter. Adenoviral infections were performed 48 h before the IP assays. The cells were infected with 100 MOI adenoviral soup in serum-free DMEM for 3 h and incubated in normal DMEM with 10% FBS.
IP assay
Calcium signaling
Cells were grown on poly-l-lysine-coated glass cover slips for 24 -48 h before experiment and incubated in a physiological solution (138 mm NaCl, 6 mm KCl, 1 mm MgSO 4 , 2 mm CaCl 2 , 1 mm Na 2 HPO 4 , 5 mm NaHCO 3 , 5 mm glucose, 10 mm HEPES, and 0.1% BSA) with 5 m fura-2/AM (Molecular Probes, Eugene, OR) at 25 C for 45 min. In the bis-(o-aminophenoxy)-ethane-N,N,NЈ,NЈ-tetraacetic acid, tetra(acetoxymethyl)-ester (BAPTA-AM) experiments, 1 m of BAPTA-AM (Calbiochem, La Jolla, CA) was coincubated with fura-2/AM. For pharmacological inhibitor experiments, the cells were preincubated with 100 m dantrolene (Sigma) or 1 m U73122 (Sigma) for 20 min before calcium imaging. To determine the Ca 2ϩ concentration in the internal Ca 2ϩ pool, 5 m thapsigargin (Tg) (Sigma), a sarcoendoplasmic Ca 2ϩ -ATP inhibitor was treated. The cells were washed twice with the dye-free physiological solution and mounted in an acrylamide chamber that allows perfusion of incubation medium. Fura-2/AM fluorescence was measured at excitation wavelengths 340 and 380 nm and at an emission wavelength 510 nm using an IX70 fluorescence microscope (Olympus, Tokyo, Japan) coupled to a digital Cool CCD camera (CoolSNAP fx CCD Camera, Roper Scientific, Tucson, AZ). All calcium data were analyzed by MetaFluor (version 5; MetaFluor, West Chester, PA).
Thymidine incorporation assay
Cells (5 ϫ 10 4 cells/well) were seeded in 12-well plates. After a 24-h preincubation, cells were treated with GnRHs or GnRH antagonists for 48 h and then further incubated with 1 Ci/ml 3 H-thymidine (NEN Life Science Products, Inc., Boston, MA) for 24 h. The cells were washed twice with cold PBS and treated with 1 ml 5% trichloroacetic acid at 4 C for 30 min. Cells were washed with PBS and solubilized in 0.5 n NaOH and 0.5% SDS. Radioactivity was counted with a liquid scintillation counter.
4Ј,6-Diamidino-2-phenylindole (DAPI) staining
The morphology of nuclei was analyzed by DAPI staining. Cells (8 ϫ 10 4 cells) were seeded on poly-l-lysine-coated glass cover slips in 6-well plates. After treatment with GnRH antagonists for 72 h, the cells were washed twice with PBS and fixed with 2% paraformaldehyde in PBS for 15 min at room temperature. After rinsing and permeabilization with 0.2% Triton X-100, the cells were washed and stained with the DAPI solution [0.1% Triton X-100, 2 mm MgCl 2 , 0.1 m NaCl, 100 mm 1,4-piperazine diethane sulfonic acid, 1 g/ml DAPI (pH 6.8)] for 5 min. The cells were washed and analyzed with a fluorescence microscope.
DNA fragmentation assay
Cells were seeded into 100-mm dishes at a density of 1 ϫ 10 6 per plate in 2% FBS-containing DMEM and treated with GnRH antagonists for 72 h. The cells were then harvested by scraping and incubated in lysis buffer [20 mm Tris-HCl (pH 8.0), 10 mm EDTA, 0.5% Triton X-100] for 30 min on ice. The homogenates were centrifuged at 15,000 rpm for 15 min. The supernatants were collected and extracted with equal volume of phenol-chloroform-isoamylalcohol. DNA was precipitated overnight with 70% ethanol at Ϫ70 C, and the pellets were washed with 70% ethanol, air dried, and dissolved in distilled water. The DNA was treated with RNase at 37 C for 15 min. The DNA was electrophoresed on a 1.5% agarose gel.
Terminal deoxynucleotidyltransferase-mediated deoxyuridine 5-triphosphate nick-end labeling (TUNEL)
To analyze DNA fragmentation histologically, TUNEL was performed using an in situ cell death detection kit, POD (Roche Diagonastics Corp., Indianapolis, IN). Cells were seeded onto poly-l-lysine-coated glass cover slips in 6-well plates at a density of 10 5 cells/well. After 24 h, the cells were treated with GnRH antagonists for 72 h. The cells were rinsed with PBS at 25 C and fixed with 4% paraformaldehyde in PBS for 1 h at room temperature. Peroxidase activity in cells was blocked with 3% H 2 O 2 in methanol for 15 min at room temperature. The cells were then permeabilized with 0.1% Triton X-100 and 0.1% sodium citrate for 2 min on ice. The cells were incubated in 50 l of TUNEL reaction mixture (Roche Diagonastics) at 37 C for 1 h in a humidified atmosphere in the dark, then rinsed three times with PBS for 5 min, and dried. The cover slips were incubated in 50 l converter-POD in a humidified chamber at 37 C for 30 min, washed three times with PBS, and incubated in 50 l of diaminobenzidine tetrahydrochloride at 25 C for 10 min. Finally, the cover slips were washed three times and analyzed on a light microscope. ]-GnRH-II (100,000 cpm) in the presence or absence of graded concentrations of cold GnRHs at 20 C for 30 min. Dishes were irradiated under an auto-cross-linking mode three times at a distance of 2 cm from the UV source in Stratalinker 2400 (Stratagene, La Jolla, CA). The cells were harvested in ice-cold binding buffer [10 mm HEPES, 1 mm EDTA (pH 7.4)], homogenized with 15 strokes of a glass Dounce homogenizer, and centrifuged for 10 min at 400 ϫ g to remove nuclei (35) . The supernatants were centrifuged at 10,000 ϫ g for 30 min at 4 C and membrane pellets were resuspended in binding buffer. Labeled receptors were denatured by adding 0.5% SDS and 1% Triton X-100 and heated at 60 C for 15 min. Samples were mixed with SDS sample buffer containing 5% (vol/vol) 2-mercaptoethanol and electrophoresed at room temperature for 18 h on three-phase polyacrylamide gels (4, 10, and 16.5% polyacrylamide) using a tricine buffer system. The gels were fixed and subjected to autoradiography.
Photoaffinity labeling
Data analysis
Results were expressed as mean Ϯ sem. Plots were produced using PRISM2 software (GraphPad, San Diego, CA).
Results
Androgen-independent prostate cancer cells bind to GnRH-II with a higher affinity than GnRH-I
To examine whether prostate cancer cells bind to GnRH-I or GnRH-II, we employed three different androgen-independent prostate cancer cell lines, DU-145, ALVA-41, and PPC1, a bladder carcinoma cell line TSU-Pr1 (36) (Fig. 1B) . The binding affinity of ALVA-41, PPC-1, and TSU-Pr1 cells for GnRH-I and GnRH-II was examined. All three cell types showed a higher affinity for GnRH-II than GnRH-I as observed in DU-145 cells (Fig. 1C) . The binding affinity of LNCaP cells for GnRH-I and GnRH-II was examined. LNCaP cells did not specifically bind to 125 I-GnRH-I. For GnRH-II, however, the LNCaP cells have a low-affinity binding because a GnRH-II analog [Tyr 5 ]GnRH-II significantly inhibited the binding, although native and other GnRH-II analogs did not (Fig. 1D) (Fig. 1E) , suggesting specific binding of 125 I-GnRH-II. Binding of DU-145 cells to 125 IGnRH-II was inhibited by unlabeled GnRH-II and salmon GnRH in a dose-dependent manner (Fig. 1F) . These results indicate that GnRH-II specifically binds to prostate cancer cells, although it has a relatively low affinity.
RT-PCR analysis of GnRH receptors in prostate cancer cells
Because the binding assay indicates the presence of a receptor with a higher affinity to GnRH-II than GnRH-I, the presence of mRNAs for already known human mammalian type 1 and type 2 GnRH receptors was sought using RT-PCR. It should be noted that 35 rounds of PCR amplification brought about very faint signals for each GnRH receptor, whereas 40 rounds of PCR amplification produced intense signals for all receptors (Fig. 2) . ALVA-41 and DU-145 cells expressed the mRNA for type 1 GnRH receptor. Interestingly, the mRNAs for individual exon 1 or exon 2 of the human type 2 GnRH receptor were amplified in all cell lines. However, we failed to obtain PCR products consisting of exon 1 and exon 2 together (Fig. 2) . This result is consistent with a previous observation that mRNA specific for human type 2 GnRH receptor is expressed ubiquitously, but the full-length mRNA may be truncated due to inappropriate posttranscriptional processing (25) . This result indicated that high-affinity binding of GnRH-II to prostate cancer cells is not due to expression of the conventional type 2 GnRH receptor.
GnRHs failed to induce IP production in prostate cancer cells
It is well known that both mammalian type 1 and type 2 GnRH receptors are coupled to G q/11 , producing IP through PLC activation. To examine the presence of functional conventional GnRH receptors, we determined IP production in response to GnRH stimulation. Treatment of prostate cancer cells with GnRHs failed to increase IP formation (Fig. 3) . One may suggest that the GnRH receptor in prostate cancer cells does not couple with G q/11 or that prostate cancer cells lack the G q/11 /PLC machinery. To test these possibilities, we infected prostate cancer cells with adenovirus containing a mutant bfGnRHR-2 (bfGnRHR-2-SDY) that has a high affinity for GnRH-II (30) . The cells infected with the adenovirus containing bfGnRHR-2-SDY significantly induced IP production in response to GnRH (Fig. 3) . However, the cells infected with adenovirus with EGFP did not respond to GnRH stimulation. Similar results were observed with MCF-7, a breast cancer cell-line and CV-1, a monkey kidney cell line (Fig. 3) . These results indicate that prostate cancer cells contain the functional G q/11 and PLC system and thus may express an uncharacterized GnRH receptor that does not link to the G q/11 /PLC system. Because GnRH did not induce IP production in prostate cancer cells, we examined other signaling systems, such as cAMP: GnRH did not alter basal or forskolin-induced cAMP levels (data not shown).
GnRHs induce calcium mobilization in prostate cancer cells
Although GnRH failed to influence IP or cAMP production, both GnRH-I and GnRH-II provoked an increase in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) in prostate cancer cells (Fig. 4) . All androgen-independent prostate cancer cells, ALVA-41, DU-145, and PPC-1, responded to both GnRH-I and GnRH-II. TSU-Pr1 cells responded to only GnRH-II. Concurrently androgen-sensitive LNCaP cells and nonprostate MCF-7 and HEK-293 cells did not respond to either GnRH-I or GnRH-II (Fig. 4) . BAPTA-AM is known to effectively chelate Ca 2ϩ release from internal stores but is not as effective at chelating Ca 2ϩ entering through plasma membrane channels (37 (Fig. 5B) . These observations indicate that GnRH-II causes [Ca 2ϩ ] i increase via mobilization of intracellular stores, whereas GnRH-I provokes Ca 2ϩ influx probably through activation of a certain Ca 2ϩ channel. Furthermore, graded concentrations of GnRH-I and GnRH-II were applied to DU-145 cells. In Ca 2ϩ -free medium, the log EC 50 value of GnRH-II was Ϫ8.21 Ϯ 0.08, whereas the log EC 50 value of GnRH-I was very high (Ϫ5.25 Ϯ 0.10), such that GnRH-II appeared to be 1000 times more potent than GnRH-I in this condition (Fig. 5C ). In the BAPTA-AM-pretreated cells, however, GnRH-I (log EC 50 Ϫ7.96 Ϯ 0.10) was more potent than GnRH-II (log EC 50 Ϫ6.57 Ϯ 0.07) (Fig. 5D) 
GnRH-II activates the ryanodine receptor to release Ca 2ϩ
The release of Ca 2ϩ from internal stores may be mediated by either the IP 3 receptor or ryanodine receptor. To determine which mechanism was responsible for GnRH-IIinduced Ca 2ϩ mobilization, cells were treated with U73122, a PLC inhibitor, or dantrolene, a ryanodine receptor inhibitor. In Ca 2ϩ -free medium, GnRH-I induced an increase of [Ca 2ϩ ] i in GH 3 cells stably expressing rat GnRHR. This increase was inhibited by U73122 but not by dantrolene, indicating that the [Ca 2ϩ ] i increase induced by rat GnRHR can be accounted for by Ca 2ϩ mobilization from IP 3 -sensitive intracellular sources (Fig. 6A) . In contrast, in DU-145 cells, the GnRH-II-induced [Ca 2ϩ ] i increase was completely blocked by dantrolene but not U73122 (Fig. 6B) . Involvement of G i coupling or receptor tyrosine kinase in GnRH-induced Ca 2ϩ mobilization was determined using pertussis toxin, an inhibitor of G i , and genistein, an inhibitor of tyrosine protein kinase. Neither of these inhibitors affected Ca 2ϩ mobilization by GnRH-I and GnRH-II in DU-145 cell (data not shown). These data, together with the observation that neither GnRH-I nor GnRH-II-induced IP 3 production in prostate cancer cells, strongly suggest that the GnRH-II-induced [Ca 2ϩ ] i increase is mediated by the ryanodine receptor rather than the IP 3 receptor.
Effect of GnRH antagonists on [Ca 2ϩ ] i
Two types of GnRH antagonists were used to study the pharmacological characteristics of GnRH-induced [Ca 2ϩ ] i transients: cetrorelix, a potent GnRH-I antagonist, and trptorelix-1 and trptorelix-2, potent GnRH-II antagonists (22, 29 ] i by GnRH-I and GnRH-II were examined in fura-2/AM-preloaded cells. The fura-2/AM 340:380 ratio of individual cells was determined. Arrows indicate exposure to GnRH-I or GnRH-II (10 nM) each. The cells that did not respond to GnRH were subsequently exposed to 1 M Tg or 1 nM ionomycin.
onists induced an increase in [Ca 2ϩ ] i , whereas high concentrations of antagonists did not (Fig. 7A) (Fig. 7B) .
A GnRH-II antagonist induces prostate cancer cell death
Because GnRHs are known to influence prostate cancer cell proliferation, we examined the effects of GnRHs and their antagonists on thymidine incorporation in DU-145 and ALVA-41 cells. GnRH-II and cetrorelix did not affect thymidine incorporation, whereas trptorelix-1 reduced thymidine incorporation in a dose-dependent manner (Fig. 8) . Despite the failure of [Ca 2ϩ ] i induction in LNCaP cells by GnRH-I and GnRH-II, LNCaP cells may have a low-affinity GnRH-II binding protein (Fig. 1D) . In addition, trptorelix-1 has a growth-inhibitory effect on LNCaP cells (data not shown). This observation suggests that trptorelix-1 could be useful for the treatment of prostate cancer cells that retain some sensitivity to androgens as well as androgen-independent cancer cells. To determine whether the trptorelix-1-induced decrease in thymidine incorporation was due to a decreased proliferation rate or an increased cell death, cellular morphology and DNA fragmentation were examined in cetrorelix-or trptorelix-1-treated DU-145 and ALVA-41 cells. Marked changes in cellular morphology were seen in trptorelix-1-but not cetrorelix-treated cells. When cells were stained with DAPI, fragmented nuclei and cells lacking nuclei were observed in trptorelix-1-treated cells (Fig. 9A) . To further confirm that trptorelix-1 induced apoptosis of pros- tate cancer cells, DNA fragmentation was visualized by electrophoresis and TUNEL. DNA laddering, and TUNEL-positive cells were observed only in the trptorelix-1-treated group (Fig. 9, B and C) .
GnRH-II antagonist induces a decrease in Ca 2ϩ concentration of internal stores
It is well known that depletion of internal Ca 2ϩ pools induces apoptosis of cells (38, 39) . To elucidate the possible mechanism for trptorelix-1-induced cell death, we examined pool (40) . Tg-releasable Ca 2ϩ was greatly reduced in trptorelix-1-treated cells, compared with control and the cetrorelix-treated group (Fig. 10) . This finding indicates that trptorelix-1 may affect Ca 2ϩ homeostasis in prostate cancer cells.
Photoaffinity labeling of GnRH-II binding protein in prostate cancer cells
The presence of a novel GnRH-II binding protein in prostate cancer cells was investigated by photoaffinity labeling using an azidobenzoyl-conjugated GnRH-II. ]-GnRH-II was dose-dependently decreased by cold natural GnRH-II but not GnRH-I (Fig. 11C) . It should be noted that there were many other bands whose intensities were decreased by cold azidobenzoyl-d-Lys 6 -GnRH-II, but the 80-kDa band was the only one whose intensity was decreased by cold native GnRH-II.
Discussion
The present study has demonstrated differential effects of GnRH-I and GnRH-II on signaling and proliferation of androgen-independent prostate cancer cells (Table 1) . Although these cells express transcripts for either conventional mammalian type 1 and/or type 2 GnRH receptors, however, the amount of protein translated from the transcript for the type 1 receptor must be very low because we did not observe specific binding of GnRH-Ia to these cells. Protein translated from the type 2 receptor transcript may be truncated or abnormal because we failed to obtain the transcript consisting of exon 1 and exon 2 together. Furthermore, the responses to GnRHs in prostate cancer cells were completely different from those found in cells expressing conventional mammalian type 1 or type 2 GnRH receptors.
Conventional GnRH receptors are known to induce ing to mobilization of IP 3 -sensitive intracellular Ca 2ϩ stores (16) . In contrast, GnRHs failed to induce IP 3 formation in prostate cancer cell. This failure of GnRH to activate polyphosphoinositide turnover is not due to a defect of the signaling machinery, such as a lack of G q/11 or PLC, in prostate cancer cells because we observed GnRH-induced IP 3 production when a conventional GnRH receptor was introduced into these cells. Interestingly, the GnRH-II-induced increase in [Ca 2ϩ ] i was completely blocked by a ryanodine receptor antagonist but not by a PLC inhibitor, indicating that GnRH-II in prostate cancer cells causes Ca 2ϩ mobilization through activation of the ryanodine receptor. However, the signaling cascade that is responsible for activation of the ryanodine receptor remains to be elucidated. release at higher concentrations (41, 42) . GnRH-II antagonists, however, may not directly affect the ryanodine receptor activation because trptorelix-1 and cetrorelix failed to induce the [Ca 2ϩ ] i in the absence of Ca 2ϩ source. Thus, it is likely that, in prostate cancer cells, the GnRH antagonists can act as agonists for the GnRH-I receptor under a certain condition. In support of this notion, we found that TSU-Pr1 cells, which responded to only GnRH-II but not GnRH-I, were not affected by trptorelix-1 and cetrorelix. Furthermore, the molecular mass of the protein that binds to GnRH-II in prostate cancer cells is approximately 80 kDa, whereas that of the conventional GnRH receptors is 40 -50 kDa (15, 35, 43) . Altogether these results strongly suggest that GnRH-II exerts its action through a novel GnRH-II binding protein in androgen-independent prostate cancer cells. However, we do not exclude the possibility that GnRH-II could act through the mammalian GnRH-I receptor because the ligand selec- Several lines of evidence also support the idea of a functional receptor for GnRH-II in humans. In human T cells, either GnRH-I or GnRH-II can induce laminin receptor gene expression and cell migration. Interestingly, the effect of GnRH-I is completely blocked by cetrorelix, whereas the effect of GnRH-II is not (12) . In human ovarian cancer cells, cetrorelix also exerts an antiproliferative effect in very much the same as GnRH-I agonists, indicating that the distinction between GnRH-I agonists and antagonists may not apply to the GnRH-I system (17) . When GnRH-I receptors are depleted in human ovarian cancer cells, the antiproliferative effect of a GnRH-I agonist is abolished, whereas the effects of a GnRH-I antagonist and GnRH-II are still observed (44) , indicating that the effect of GnRH-I antagonists and GnRH-II in these cells are not mediated by the conventional GnRH-I receptor.
Prostate cancer develops from an androgen-dependent stage to an androgen-independent stage. It is likely that during the androgen-dependent stage, the main effect of GnRH analogs as prostate cancer therapy is to block or to desensitize the pituitary type 1 GnRH receptor, thereby reducing serum androgen levels (3) (4) (5) , whereas during the androgen-independent stage, GnRH-I and GnRH-II may act directly on prostate cancer cells. According to our findings, GnRH-I and GnRH-II themselves are not likely to affect proliferation of prostate cancer cells as neither peptide altered thymidine incorporation. However, the [Ca 2ϩ ] i increase induced by GnRHs indicates a possible role of GnRHs in cancer cell activity. Indeed, cytosolic Ca 2ϩ is known to control numerous cell functions, including contraction, proliferation, differentiation, and migration (40, 45, 46) . Although the exact regulatory role of GnRHs in prostate cancer cells is currently unknown, it is conceivable that GnRH-I and/or GnRH-II may affect gene expression and/or cell migration in androgen-independent prostate cancer cells. In particular, ryanodine receptor activation by GnRH-II in prostate cancer cells is likely important because activation of these receptors is involved in the control of cell migration (46) .
To elucidate the role of GnRHs in prostate cancer cell regulation, it is also of interest to determine the sources of endogenous GnRHs. The GnRH-I and/or GnRH-II genes are expressed in a number of peripheral tissues such as placenta (8) , T cells (12), breast (10), endometrium (9) , and ovarian surface cells (47) . However, the GnRH peptides produced from these tissues are generally thought to play an autocrine or paracrine role rather than endocrine activities. Considering the extremely short half-life of GnRHs, an endocrine action of the peptides would not be expected. Because the GnRH genes are expressed in prostate cancer cells (6, 48) , it seems likely that GnRHs can act as paracrine or autocrine factors in prostate cancer development. Therefore, regulation of the GnRH-I and GnRH-II genes during prostate cancer differentiation, and biosynthesis of GnRH from these transcripts deserve further investigation. An interesting finding in this study is that trptorelix-1 induced prostate cancer cell death, probably through apoptosis. Although there are numerous reports indicating that GnRH analogs decrease proliferation of a variety of reproductive tissue cancer cells (14, 17, 43, 44, 49 -51) , few of them have shown that a GnRH analog can induce cancer cell death. The mechanism involved in trptorelix-1-induced apoptosis of prostate cancer cells is currently a matter of speculation. A possible explanation is that trptorelix-1 may disturb Ca 2ϩ homeostasis because high concentrations of trptorelix-1 completely blocked either GnRH-I-or GnRH-II-induced [Ca 2ϩ ] i increase. It is well established that depletion of internal Ca 2ϩ pools induces apoptosis of cells (38, 39) . Moreover, Ca 2ϩ mobilization via the ryanodine receptor is known to play a role in apoptosis of androgen-dependent prostate cancer cells (52) . Indeed, we observed that trptorelix-1, but not cetrorelix, decreased Ca 2ϩ concentration in internal store. Alternatively, it is possible that trptorelix-1 can induce apoptosis through a yet-unknown mechanism.
In conclusion, GnRH-I agonists and antagonists are already widely used in various reproductive tissue cancer therapies. However, the direct effects of GnRH-II agonists and antagonists have been barely examined in these cancer cells, although many of them are responsive to GnRH-II (38) . Whether these cancer cells express novel GnRH-II receptors, as observed in prostate cancer cells, and whether GnRH-II antagonists can induce their death needs to be elucidated. This study provides evidence that androgen-independent prostate cancer cells possess novel receptors for GnRH-I and GnRH-II. Further information on these receptors will facilitate development of new drugs for the treatment of reproductive tissue cancers.
